Alamo Group (ALG) Q3 Earnings Miss Estimates
Alamo Group (ALG) came out with quarterly earnings of $2.34 per share, missing the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.38 per share a year ago.
Alamo Group Inc. (ALG) Q2 2025 Earnings Call Transcript
Alamo Group Inc. (NYSE:ALG ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Agnieszka K. Kamps - Executive VP, CFO, Interim Chief Accounting Officer& Treasurer Edward T.
Alamo Group (ALG) Lags Q2 Earnings Estimates
Alamo Group (ALG) came out with quarterly earnings of $2.57 per share, missing the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.35 per share a year ago.
Why Alamo Group (ALG) is Poised to Beat Earnings Estimates Again
Alamo Group (ALG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
As Wall Street faces mixed moves in July, NVS, ALG, MT, BILI and STRL stand out as low-leverage stocks to weather volatility.
Are You Looking for a Top Momentum Pick? Why Alamo Group (ALG) is a Great Choice
Does Alamo Group (ALG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Alamo Group Inc (ALG) Q1 2025 Earnings Call Transcript
Alamo Group Inc (NYSE:ALG ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Edward Rizzuti - Executive Vice President, Corporate Development, Investor Relations Jeffery Leonard - President and Chief Executive Officer Agnes Kamps - Executive Vice President and Chief Financial Officer Conference Call Participants Christopher Moore - CJS Securities Linda Umwali - D.A. Davidson Gregory Burns - Sidoti & Company Mircea Dobre - Baird Operator Good morning, and welcome to the Alamo Group's First Quarter 2025 Conference Call.
Alamo Group Inc (ALG) Q4 2024 Earnings Call Transcript
Alamo Group Inc (NYSE:ALG ) Q4 2024 Earnings Conference Call February 28, 2025 10:00 AM ET Company Participants Edward Rizzuti - Executive Vice President, Corporate Development, Investor Relations Jeff Leonard - President and Chief Executive Officer Agnes Kamps - Executive Vice President and Chief Financial Officer Conference Call Participants Mike Shlisky - D.A. Davidson Chris Moore - CJS Securities Greg Burns - Sidoti & Company Peter Kalemkerian - Robert W.
New Strong Sell Stocks for January 6th
ALG, ASHTY and YOU have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2024.
New Strong Sell Stocks for December 9th
ALG, GEF and HTCMY have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2024.
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activation in the tumor microenvironment Data Presented at Society for Immunotherapy of Cancer on November 8, 2024 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / November 11, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced preliminary data from the companies' Phase 1 trial evaluating the first-in-class bispecific antibody, ALG.APV-527, as monotherapy for the treatment of multiple solid tumor types likely to express tumor antigen 5T4. These data indicate that trial endpoints of adequate exposure, safety, tolerability and biological activity were met.
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable disease Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activation in the tumor microenvironment Data Presented at Society for Immunotherapy of Cancer on November 8, 2024 SEATTLE, WA and LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced preliminary data from the companies' Phase 1 trial evaluating the first-in-class bispecific antibody, ALG.APV-527, as monotherapy for the treatment of multiple solid tumor types likely to express tumor antigen 5T4. These data indicate that trial endpoints of adequate exposure, safety, tolerability and biological activity were met.
